key: cord-0913612-kibm5ye3
authors: da Silva, Luís Cláudio Nascimento; Mendonça, Juliana Silva Pereira; de Oliveira, Weslley Felix; Batista, Karla Lílian Rodrigues; Zagmignan, Adrielle; Viana, Isabelle Freire Tabosa; Santos Correia, Maria Tereza
title: Exploring lectin-glycan interactions to combat COVID-19: lessons acquired from other enveloped viruses
date: 2020-10-21
journal: Glycobiology
DOI: 10.1093/glycob/cwaa099
sha: ba7f523dc5d036f62e7d9f387cde180592fc46f1
doc_id: 913612
cord_uid: kibm5ye3

The emergence of a new human coronavirus (SARS-CoV-2) has imposed great pressure on the health system worldwide. The presence of glycoproteins on the viral envelope opens a wide range of possibilities for application of lectins to address some urgent problems involved in this pandemic. In this work, we discuss the potential contributions of lectins from non-mammalian sources in the development of several fields associated with viral infections, most notably COVID-19. We review the literature on the use of non-mammalian lectins as a therapeutic approach against members of the Coronaviridae family, including recent advances in strategies of protein engineering to improve their efficacy. The applications of lectins as adjuvants for antiviral vaccines are also discussed. Finally, we present some emerging strategies employing lectins for the development of biosensors, microarrays, immunoassays and tools for purification of viruses from whole blood. Altogether, the data compiled in this review highlights the importance of structural studies aiming to improve our knowledge about the basis of glycan recognition by lectins and its repercussions in several fields, providing potential solutions for complex aspects that are emerging from different health challenges.

The year of 2020 has been marked by the global dissemination of a new type of severe acute respiratory syndrome, defined as COVID-19 (Rothan, H.A. and Byrareddy, S.N. 2020, Yi, Y., Lagniton, P.N.P., et al. 2020) . The initial symptoms of COVID-19 disease are similar to the common cold. However, this infection can progress to severe respiratory failure with impaired and deleterious immunological responses (Li, R., Tian, J., et al. 2020 , Sun, S., Cai, X., et al. 2020 , Xu, B., Fan, C.Y., et al. 2020 ). This state is characterized by increased ratios of monocytes and neutrophils and exacerbated release of inflammatory mediators (especially IL-6) that may contribute to dysfunction of multiple organs (Qin, C., Zhou, L., et al. 2020 , Xu, B., Fan, C.Y., et al. 2020 . Despite the occurrence of other coronavirus outbreaks, there is still no specific therapy or vaccine for COVID-19 (Alanagreh, L., Alzoughool, F., et al. 2020 , Pastick, K.A., Okafor, E.C., et al. 2020 .

Other important concern is the urgent need for simple and fast devices for viral detection in clinical and environmental samples (Liang, K.H., Chang, T.J., et al. 2020 , Qiu, G., Gai, Z., et al. 2020 . Particularly, the early detection of SARS-CoV-2 in asymptomatic and/or presymptomatic individuals is important to break the chain of transmission (Arons, M.M., Hatfield, K.M., et al. 2020 , Furukawa, N.W., Brooks, J.T., et al. 2020 . The

extracorporeal removal of SARS-CoV-2 from blood by plasmapheresis is also important for implementation of alternative therapies (Turgutkaya, A., Yavasoglu, I., et al. 2020 ). This complex panorama has imposed a race against time across different fields of knowledge (biomedical science, biotechnology, drug development, molecular analysis, etc.) to offer the maximum number of solutions to these and other issues raised by this pandemic (Venkatakrishnan, K., Yalkinoglu, O., et al. 2020 ).

SARS-CoV-2 has a lipoprotein envelope surrounding the infectious virion particles which is derived from the host cell during the budding (Bianchi, M., Benvenuto, D., et al. 2020, Sternberg, A. and Naujokat, C. 2020) . The viral envelope has two layers of lipids whose composition depends on the type of membrane from which this structure is derived (Cosset, F.L. and Lavillette, D. 2011) . The proteins are interspersed in the lipid layers and some of them are glycosylated by hots enzymes (Carbaugh, D.L. and Lazear, H.M. 2020, Cipollo, J.F. and Parsons, L.M. 2020) . Like other enveloped viruses, the envelope glycoproteins of SARS-CoV-2 are involved in the process of viral adhesion and entry (Sternberg, A. and Naujokat, C. 2020, Verma, J., Subbarao, N., et al. 2020) .

For instance, the envelope of SARS-CoV-2 exhibits glycoproteins such as spike (Sprotein) and membrane (M-protein) proteins (Ahmed, S.F., Quadeer, A.A., et al. 2020 , Shajahan, A., Supekar, N.T., et al. 2020 ) (Supplementary Figure 1A) . These structural proteins (specially S-protein) exert central roles in viral pathogenesis and are pointed as important targets for neutralizing antibodies, vaccine and drug design (Ahmed, S.F., Quadeer, A.A., et al. 2020, Bagdonaite, I. and . Besides, non-structural proteins are also found in glycosylated forms, such as the 3a protein, which plays an essential role in SARS-CoV-2 virulence (Fung, T.S. and Liu, D.X. 2018, Issa, E., Merhi, G., et al. 2020) . The presence of glycoproteins in viral envelope opens a wide range of possibilities for application

of carbohydrate binding agent, such as lectins, to address some urgent problems involved in this pandemic situation.

Lectins comprises a large class of proteins sharing the ability to recognize specific types of carbohydrates residues (Coelho, L.C., Silva, P.M., et al. 2017) . They are ubiquitously distributed in the organisms where participate in sugar storage, immune defense systems and other physiological processes (Brown, G.D., Willment, J.A., et al. 2018 , Prado Acosta, M. and Lepenies, B. 2019 , Ribeiro, A.C., Monteiro, S.V., et al. 2014 . Moreover, lectins from pathogenic agents (including viruses, bacteria and fungi) are involved in their virulence mechanisms through binding to glycans present on host cell surfaces (Landi, A., Mari, M., et al. 2019 , Patra, D., Mishra, P., et al. 2014 , Van Breedam, W., Pohlmann, S., et al. 2014 ). Swanson, M.D., Boudreaux, D.M., et al. 2015) . Importantly, these agglutinins are pointed as broad-spectrum inhibitors of viral invasion, since they could target sugar moieties in surface proteins and block the adhesion to host cells (Gondim, A.C.S., Roberta da Silva, S., et al. 2019 , Mitchell, C.A., Ramessar, K., et al. 2017 , Wang, D., Tang, J., et al. 2015 . The interaction with glycoproteins also allows the use of lectins in the development of devices for identification and characterization of glycoproteins in viral envelope or alterations in host glycoproteins during viral infection , Simao, E.P., Silva, D.B.S., et al. 2020 ).

Herein, we discuss the potential contributions of non-mammalian lectins in the development of different fields of viral infections research, using COVID-19 disease as background. Given the recent emergence of the SARS-CoV-2, we review some lessons acquired from previous studies on closely related coronaviruses (SARS-CoV, MERS-CoV)

and other enveloped viruses. In this regard, the possible applications of lectins include: (i) design of leading molecules for antiviral therapy; (ii) development of adjuvant compounds for immunization; (iii) establishment of approaches to characterize glycosylation of viruses or infected host protein structures; (iv) development of devices for viral detection and purification. We also discuss challenges and limitations for each target application.

Glycosylation is the most common type of post-translational modification (PTM), which significantly regulates the structure (folding and stability) and functions of proteins (Cipollo, J.F. and Parsons, L.M. 2020, Ohyama, Y., Nakajima, K., et al. 2020) . Glycans are involved in viral adhesion and epitope shielding from antibody recognition, therefore glycosylation sites may be under selective pressure (Vankadari, N. and Wilce, J.A. 2020, Watanabe, Y., Bowden, T.A., et al. 2019) . The synthesis, folding and glycosylation (as other PTMs) of viral proteins depend on host organelles (ribosomes, endoplasmic reticulum and Golgi apparatus) and enzymes (glycotransferases and glycosidases) (Carbaugh, D.L. and Lazear, H.M. 2020, Cipollo, J.F. and Parsons, L.M. 2020 ).

The current experimental data regarding the glycosylation of viral proteins is dependent on the carbohydrate processing enzymes available in the biological systems used to

propagate the viral strain. In this sense, our knowledge about the natural pattern of viral glycosylation is very limited (Bagdonaite, I., Vakhrushev, S.Y., et al. 2018, Cipollo, J.F. and Parsons, L.M. 2020) . It is also important to consider that viral proteins may follow different pathways than those observed from host glycoproteins (Watanabe, Y., Bowden, T.A., et al. 2019) .

The covalent addition of glycans in viral proteins occurs mainly through two pathways: (i) N-glycosylation, when the glycan is connected to asparagine (Asn) residues;

and (ii) O-glycosylation, when the modification is performed in oxygen atoms of serine (Ser) and threonine (Thr) residues [sometimes tyrosine (Tyr) residues are used] (Watanabe, Y., Bowden, T.A., et al. 2019) . The mucin-type O-glycosylation, also known as Nacetylgalactosamine (GalNAc)-type, is the most commonly observed in viral proteins (Chen, N., Kong, X., et al. 2020, Hargett, A.A. and Renfrow, M.B. 2019 ).

The process of N-glycosylation of viral proteins in mammalian cells starts in parallel with their synthesis. In the cytoplasmatic side of endoplasmatic reticulum (ER), the glycan precursor is synthesized containing three glucose (Glc), nine mannose (Man), and two Nacetylglucosamine (GlcNAc) (Glc 3 Man 9 GlcNAc 2 ) glycosylation sites (Hargett, A.A. and Renfrow, M.B. 2019 ). This precursor is transferred to the ER lumen and modified by the addition of monosaccharides (Fung, T.S. and Liu, D.X. 2018) .

The mature glycan structure is then added, by an oligosaccharyltransferase, to the Asn residue of an Asn-X-Ser/Thr motif ('X' in any amino acid, except proline) in the nascent This is a trimeric protein that mediates the viral adhesion through binding to the human angiotensin-converting enzyme 2 (hACE2) and also interacts with the host immune defense (Ou, X., Liu, Y., et al. 2020, Vankadari, N. and The S-protein from SARS-CoV-2 has two functional subunits (S1 and S2) with 22 and 3 potential sites for N-glycosylation and O-glycosylation, respectively (Andersen, K.G., Rambaut, A., et al. 2020 , Watanabe, Y., Allen, J.D., et al. 2020 . Despite the similarity with SARS-CoV spike (approximately 87.2%), some differences in the glycosylation sites repertoire and known epitopes have been reported for SARS-CoV-2 spike (Kumar, S., Maurya, V.K., et al. 2020 , Vashi, Y., Jagrit, V., et al. 2020 . For instance, it exhibits an unusual cleavage site for the furin protease between the S1/S2 subunits, which is not observed in SARS-CoV. The N-linked glycans were recently mapped by cryoelectron microscopy in 16

amino acid residues of the S-protein expressed in HEK293F cells (from human embryonic kidney) (Walls, A.C., Park, Y.J., et al. 2020 ).

More details on N-glycosylation profiles of the 22 sites were unraveled using recombinant proteins expressed in HEK293F cells. The oligomannose-type glycans were predominant in two sites (N234 and N709). Complex-type glycans were predominantly 

host cell receptors.

As previously mentioned, the S-protein of SARS-CoV-2 has a crucial role in viral adhesion by binding to hACE2. Therefore, the disruption of this interaction is considered an attractive target for antiviral therapy (Batlle, D., Wysocki, J., et al. 2020 , Ou, X., Liu, Y., et al. 2020 . Some non-mammalian derived lectins (from plants and bacteria) are pointed as alternative antiviral agents against enveloped viruses due to their ability to recognize the glycans present in the structural proteins and to impair the initial steps of viral pathogenesis Besides these insights given by the anti-SARS-CoV-2 action of FRIL, other important lessons can be learned from other SARS-CoV and related viruses (as summarized in Table I) .

For instance, a study evaluated the in vitro antiviral activity of 33 plant lectins towards coronaviruses (SARS-CoV and feline infectious peritonitis virus). Mannose-binding agglutinins showed the highest anti-SARS-CoV effects. Among the studied lectins, the higher In this case, the inhibition of host mannosidases resulted in the improved antiviral activity of

the mannose-and GlcNAc-binding lectins (van der Meer, F.J., de Haan, C. A., et al. 2007b) .

GNA was also recently reported as an inhibitor of cell entry mechanism of influenza A H3N2 (Thompson, A.J., Cao, L., et al. 2020 ).

Non-plant derived agglutinins are also pointed as promising agents against coronaviruses, e.g. the mannose-binding-lectins cyanovirin-N (from cyanobacterium Nostoc ellipsosporum) and griffithsin (from red marine alga Other relevant concern is the recognition of glycoconjugates present in host cells, 

Cyanovirin-N is one of the lectins with activity against coronaviruses and others enveloped viruses (Barrientos, L.G., Matei, E., et al. 2006 , Hu, B., Du, T., et al. 2015 , Kachko, A., Loesgen, S., et al. 2013 

crystalized (with four sugar-binding sites). The dimerization was shown to restore the viral inhibition of mutants (Matei, E., Zheng, A., et al. 2010 ).

The antiviral activity of the designed cyanovirin-N oligomers (dimers, trimers and tetramers) was evaluated against HIV. The dimers showed higher anti-HIV efficacy than the parental protein and other forms. Importantly, the dimers exhibited neutralizing activity at comparable or even superior levels than antibodies ( The derivative PEG10k-LCV-N also inhibited normal and acyclovir-resistant strains of HSV-1, even though with less action than its precursors (wild type and linked-cyanovirin-

. Despite of this, the reduction in cytotoxicity, antigenicity and mitogenicity observed for the pegylated version are important aspects that advocate for its therapeutic value (Lei, Y., Chen, W., et al. 2019) . Overall, these results with mono-PEGylated derivatives represent alternative models to increase the usefulness of lectins in antiviral therapy.

BanLec is a mannose-binding protein from the group of lectin related jacalin with tetrameric structure (two binding sites in each monomer) and remarkable anti-infective In order to improve the inhibitory action of MVN, some oligomeric versions of were designed and tested in vitro against HCV. The results showed that tri-and tetramers have higher ability to block the HCV invasion than dimers and monomers (Min, Y.Q., Duan, X.C., et al. 2017 ). Recently, a version of microvirin (LUMS1) was engineered to have two identical domains and, therefore, two carbohydrate-binding sites. Although LUMS1 showed lower sugar affinity than wild type, it was able to block HIV and HCV infectivity. Undoubtedly, the most advantageous characteristics of LUMS1 are its lower cytotoxicity and immunogenicity.

These properties should be associated to the structural homogeneity conferred by the two identical domains (Shahid, M., Qadir, A., et al. 2020) .

The production of chimeras using the cyanobacterium-derived lectins ( 

Active lectins could be also fused with broadly neutralizing antibodies ( In the first report, Avaren was fused to the antigen-binding fragment (Fab) of the CD4 binding site-specific VRC01 bNAb, which resulted in the VRC01 Fab -Avaren lectibody. In this case, VRC01 Fab -Avaren was designed to: i. target the mannose residues present in the HIV-1 gp120 glycoprotein; and ii. the binding site of gp120 on the receptor of TCD4 lymphocytes (through Avaren and VRC01, respectively). Using cell-based assays, the authors proved the The second lectibody was generated by fusion of Avaren and the crystallizable region fragment (Fc) of the human immunoglobulin G1 (Fc IgG1). It was called AvFc and showed higher affinity (approximately 10-folds) to gp120 than actinohivin. AvFc also showed higher in vitro activity towards several strains of HIV-1 and HIV-2 than its wild-type counterpart.

Employing biochemical assays, the authors showed the bispecific function of AvFc: (i) the treatment with mannosidases impaired its antiviral activity; (ii) a mutant of AvFc with reduced affinity to Fcγ receptors also showed lower action than AvFc. This lectibody did not induce toxic effects to human and mice peripheral blood mononuclear cells ( In general, the advances obtained in these studies with engineered lectins provide several lessons that could be applied in the development of therapeutic strategies against COVID-19. However, the possible adverse effects discussed above due to systemic administration of carbohydrate-binding agents need to be carefully assessed for each type of infection. In the context of COVID-19, the intranasal administration of these agents seems to

be an attractive option. However, some aspects are also important to be examined, including the tissue distribution of these macromolecules (associated with their size), their influence in tissue metabolism, engagement of cells receptors and induction of local inflammation (especially in the lower respiratory tract).

The implementation of global community immunity using vaccines is believed to be , van Doremalen, N., Lambe, T., et al. 2020 .

The majority of these initiatives are focused on the development of gene-based vaccines (including viral-or nucleic acid-vectors that encode protein antigens that are produced by host cells) and protein-based vaccines (using recombinant or synthetic antigenic proteins or subdomains, or viral proteins assembled as virus-like particles) (Gao, Q., Bao, L., et al. 2020 , Peeples, L. 2020 . The biggest challenge with these types of vaccines is the induction of long-lasting immunity, which is usually lower than the traditional approaches using live or inactivated organisms (Shi, S., Zhu, H., et al. 2019 , Vetter, V., Denizer, G., et al. 2018 .

In this scenario, the employment of powerful adjuvants is important to improve immunization efficacy. These compounds need to enhance the immune response induced by the vaccine, while keeping the equilibrium between humoral and cellular immune responses (Del Giudice, G., Rappuoli, R., et al. 2018 , Shi, S., Zhu, H., et al. 2019 ). Noteworthy to mention that even the proper induction of Th1-biased response, which is important for protection against viral infections, still remains as a limitation for some adjuvants (Golos, A. and Lutynska, A. 2015) .

Lectins are well-known to promote proliferation of lymphocytes and modulate the lymphocytes (Kim, Y., Kim, I., et al. 2018) .

The AAL molecule isolated from Agrocybe aegerita (mushroom) is another example of lectin with adjuvant properties for influenza immunization. In this study, mice were immunized by subcutaneous injection of inactivated H9N2 strain and AAL. The animals that received AAL and inactivated H9N2 exhibited higher levels of anti-influenza IgG1 and IgG2a than those treated with inactivated virus alone. By employing a recombinant-ALL with mutation in the carbohydrate-binding domain, the authors also showed that the adjuvant

properties of AAL were mediated by the recognition of glycoproteins in the viral surface (Ma, L.B., Xu, B.Y., et al. 2017) . Transcriptome analysis revealed that the adjuvant effects of AAL were associated with increased expression of genes related to leukocyte migration and lymphocyte activation (Ma, L.B., Xu, B.Y., et al. 2018) .

Although these studies show the lectins as promisor adjuvant candidates, the concerns regarding their administration listed before (agglutination of host cells, induction of undesired inflammation and proliferation) need to be considered. Specifically, long-term immunological and toxicological evaluations are required to prove the usefulness of an adjuvant compound (Shah, R.R., Hassett, K.J., et al. 2017) . The potential induction of severe systemic inflammation by lectins is also a possibility to be evaluated in the early stage of the research.

Regarding the application of lectins as adjuvants for viral vaccines (including those against SARS-CoV-2), one important challenge is to choose of a combination (vaccine/lectin) able to concomitantly promote an effective adaptive immune response with clinical safety.

The incorporation of glycans in envelope proteins has great influence in viral adhesion and recognition by the immune system, since epitopes of neutralizing antibodies are often protected by glycan molecules (Vankadari, N. and Wilce, J.A. 2020, Watanabe, Y., Bowden, T.A., et al. 2019). The differential patterns of glycosylation in a viral protein can be elucidated by lectin-based devices, e.g. lectin-microarrays and lectin-ELISA assays. This information is essential to expand our understanding about the role played by glycan shields in viral pathogenesis (Guo, Y., Yu, H., et al. 2018 , Hiono, T., Matsuda, A., et al. 2019 , Thompson, A.J., Cao, L., et al. 2020 , Wagatsuma, T., Kuno, A., et al. 2018 .

The comprehension of glycosylation of host proteins is other hot topic to be considered in the context of infectious diseases (Goncalves, B.S., Horta, M.A.P., et al. 2019 , Irvine, E.B. and Alter, G. 2020 , Kaplan, B.S. and Vincent, A.L. 2020 . The dynamic of glycosylation has been evaluated for a plethora of viral diseases (Dalal, K., Dalal, B., et al. 2019 , Major, M. and Law, M. 2019 , Qin, X., Guo, Y., et al. 2017 , Qin, Y., Zhong, Y., et al. 2016 ). In some cases, specific differential expression of these glycoconjugates is correlated with the severity degree of some conditions (Luna, D.M., Oliveira, M.D., et al. 2014 , Yeh, M.L., Huang, C.F., et al. 2019 . These experimental approaches are important to discovery and clinical validation of glycoconjugates as biomarkers for diagnosis.

The possible correlation among alterations in serum glycoproteins expression (and/or in their glycosylation patterns) and the clinical presentations of COVID-19 is another question that could be addressed by employing lectin-based tools such as lectin-affinity chromatography, lectin-microarrays and lectin-immunoassays (Lectin-ELISA). So far, some studies have associated changes in the serum constituents of patients with COVID-19 and disease severity. For example, serum levels of IL-6 and C-reactive protein had a significant correlation with the severity of the disease while the procalcitonin (a glycoprotein) may be a predictor of poor/good prognosis (Liu, F., Li, L., et al. 2020) .

The development of fast and sensitive methods for pathogens detection is essential to promote the effective treatment and to prevent their dissemination (Liang, K.H., Chang, T.J., et al. 2020 , Qiu, G., Gai, Z., et al. 2020 , Seo, G., Lee, G., et al. 2020 ). The techniques currently used for viral diagnosis comprise immunochromatography-based assays, enzymelinked immunosorbent assay (ELISA) and polymerase chain reaction (PCR and derivative assays). However, especially in the context of COVID-19, some serological tests do not

exhibit satisfactory accuracy; while the molecular assays require expensive reagents and extensive sample preparation, which may cause a delay in results (Acquah, C., Danquah, M.K., et al. 2016, Cesewski, E. and Johnson, B.N. 2020) .

Biosensors are analytical tools that have a bioreceptor element (such as a lectin), immobilized in a thin layer on the surface of the transducer. They are intended to provide specific and sensitive detection of an analyte in biological samples (de Oliveira, W.F., Dos Santos Silva, P.M., et al. 2019 , Silva, M.L.S. 2018 . A few biosensors have been proposed for SARS-CoV-2 diagnosis targeting S protein (Seo, G., Lee, G., et al. 2020) or nucleic acids (Qiu, G., Gai, Z., et al. 2020 ). In the following sub-sections, we discuss the construction of lectin-based biosensors targeting viral or host glycoproteins (Table IV) .

The intrinsic specificity of lectins towards glycans allows their use as an element of biorecognition of glycans present in viral proteins (Cesewski, E. and Johnson, B.N. 2020 , Hong, S.A., Kwon, J., et al. 2015 , Tung, Y.-T., Liang, J.-J., et al. 2019 ). In the case of SARS-CoV-2, its envelope glycoproteins could be also exploited for identification using lectin-based biosensors (as illustrated in Supplementary Figure 2C ).

An electrochemical biosensor based on Con A-modified nanostructured gold electrodes was used to detect Norovirus (non-enveloped virus) in fecal samples using Cyclic voltammetry and impedance spectroscopy analyzes. This biosensor showed high specificity and did not exhibit cross-reaction with hepatitis A or E viruses (Hong, S.A., Kwon, J., et al. 2015) . Another example of electrochemical biosensor was elaborated using cysteine, zinc oxide nanoparticles and Con A. The impedimetric response allowed the distinction of DENV-2, Zika virus, Chikungunya virus, and Yellow fever virus in serum samples (Simao, E.P., Silva, D.B.S., et al. 2020) .

Some studies have suggested that glycoproteins are differentially expressed in the serum of subjects affected by acute and chronic viral infections (such as dengue and hepatitis), making the profile of serum glycoproteins an emerging target for diagnosis (Luna, D.M., Oliveira, M.D., et al. 2014 , Yeh, M.L., Huang, C.F., et al. 2019 . In this scenario, biosensors incorporated with lectins could provide a fast identification of people infected with SARS-CoV-2 based on the profile of glycoproteins in biological fluids. This approach could be extremely interesting if SARS-CoV-2-infected subjects exhibited a differential glycosylation profile that those individuals affected by other respiratory pathogens.

Two types of Con A-based biosensors have been proposed for Dengue diagnosis using serum glycoproteins. In the first, Con A was immobilized on gold electrode using polyvinyl butyral to construct a biosensor capable to identify different glycoprotein patterns in the sera of patients with dengue fever and dengue hemorrhagic fever. The distinction was based on changes in charge transfer resistance using electrochemical impedance spectroscopy These lectin-based biosensors could represent a more cost-effective alternative when compared to those that currently use antibodies and nucleic acids (Luna, D.M., Oliveira, M.D., et al. 2014 ). However, their sensitivity and specificity could be a limitation. In particular, the binding to glycans from other sources (host or other pathogens) could induce false results. Thus, these parameters need to be effectively optimized prior their use in clinical analysis.

Plasmapheresis is the extracorporeal purification of pathogens and other products (toxins, cytokines) from blood. This could be performed in association with dialysis as a resource to reduce SARS-CoV-2 levels in the patient's blood (Turgutkaya, A., Yavasoglu, I., et al. 2020) . Indeed, this technique has been used to remove SARS-CoV-2 from convalescent plasma transfusions ) and has been considered as an alternative treatment considered for COVID-19 due the absence of vaccine or specific medication for SARS-CoV-2 (Brown, B.L. and McCullough, J. 2020, Duan, K., ).

The ability of GNA to bind mannose-containing glycans has been used to modify the plasmapheresis apparatus (Hemopurifier ® cartridges) (Supplementary Figure 2D) . The system is designed as a lectin affinity plasmapheresis (LAP) and has been employed in in vitro and clinical evaluations of viral disease. For instance, GNA-modified hemopurifier removed HCV from blood of HCV-infected patients. In vivo analysis showed that the association of this

system with dialysis was effective in reducing HCV load in the blood (Tullis, R.H., Duffin, R.P., et al. 2009 ).

Later, other study showed that the continuous blood purification using LAP resulted in undetectable viral load in HCV-positive patients. This therapy enhanced the effectiveness of standard drugs without plasma losses . A GNA-based system was also successfully applied for extracorporeal removal of Ebola virus in a patient (Buttner, S., Koch, B., et al. 2014 ). In addition to these cases, in vitro analysis with LAP devices cleared MERS-CoV and Marburg virus as well as their respective soluble glycoproteins .

Although the number of tested patients in these studies is rather limited, these results with LAP shall be considered for future applications of lectins in clinical settings (Table IV) .

Further evaluation of fluid composition after the procedures is performed needs to be conducted to rule out the possibility of removal of other important plasmatic proteins, in special neutralizing antibodies. The efficiency of these devices should be compared with other assays of pathogen inactivation.

The presence of glycoproteins in the viral envelope opens a wide range of possibilities for application of lectins to solve different types of problems involved with viral infections such as COVID-19. In the therapeutic area, the lectins could be considered leading molecules for the development of new antiviral approaches due to their ability to inhibit viral entry in the host cell. The advances in protein design strategies are important to boost the clinical application of these agents considered for treatment of SARS-CoV-2 and other viral infections. The immunomodulatory action of some lectins can also be exploited to improve the effectiveness of immunization schemes for viral infections. Similarly, the lectin-based biosensors could have low specificity due the signals from other glycans. Several interesting strategies have been applied to overcome these issues. 

Deploying aptameric sensing technology for rapid pandemic monitoring

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms. Pathogens

The proximal origin of SARS-CoV-2

Diagnosis of dengue infection using a modified gold electrode with hybrid organic-inorganic nanocomposite and Bauhinia monandra lectin

Metastable HIV-1 Surface Protein Env Sensitizes Cell Membranes to Transformation and Poration by Dual-Acting Virucidal Entry Inhibitors

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

Biosensor based on hybrid nanocomposite and CramoLL lectin for detection of dengue glycoproteins in real samples

Viral glycoproteomes: technologies for characterization and outlook for vaccine design

Global aspects of viral glycosylation

Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition

Plant lectins ConBr and CFL modulate expression tolllike receptors, pro-inflammatory cytokines and reduce the bacterial burden in macrophages infected with Salmonella enterica serovar Typhimurium

Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy

Sars-CoV-2 Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics?

Treatment for emerging viruses: Convalescent plasma and COVID-19

C-type lectins in immunity and homeostasis

Extracorporeal virus elimination for the treatment of severe Ebola virus disease--first experience with lectin affinity plasmapheresis

Flavivirus Envelope Protein Glycosylation: Impacts on Viral Infection and Pathogenesis

Lectins as mitosis stimulating factors: Briefly reviewed

Electrochemical biosensors for pathogen detection

Linker-extended native cyanovirin-N facilitates PEGylation and potently inhibits HIV-1 by targeting the glycan ligand

Post-translational modification of baculovirusencoded proteins

Glycomics and glycoproteomics of viruses: Mass spectrometry applications and insights toward structure-function relationships

Vaccine designers take first shots at COVID-19

Chimeric Cyanovirin-MPER recombinantly engineered proteins cause cell-free virolysis of HIV-1

A strategic approach to COVID-19 vaccine R&D

A molecularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection in vivo

Encapsulation into Stealth Liposomes Enhances the Antitumor Action of Recombinant Cratylia mollis

Immunomodulatory effects of pCramoll and rCramoll on peritoneal exudate cells (PECs) infected and non-infected with Staphylococcus aureus

Plant lectins and Toll-like receptors: implications for therapy of microbial infections

Analysis of serum Haptoglobin using glycoproteomics and lectin immunoassay in liver diseases in Hepatitis B virus infection

A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo

Antiviral activity of native banana lectin against bovine viral diarrhea virus and bovine alphaherpesvirus type 1

Lectin-Carbohydrate Interactions: Implications for the Development of New Anticancer Agents

Schinus terebinthifolia leaf lectin (SteLL) has anti-infective action and modulates the response of Staphylococcus aureus-infected macrophages

Correlates of adjuvanticity: A review on adjuvants in licensed vaccines

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Post-translational modifications of coronavirus proteins: roles and function

Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic

Rapid development of an inactivated vaccine candidate for SARS-CoV-2

Mushroom lectin enhanced immunogenicity of HBV DNA vaccine in C57BL/6 and HBsAgtransgenic mice

Aluminium-adjuvanted vaccines--a review of the current state of knowledge

Dynamics of nonstructural glycoprotein-1 in dengue patients presenting with different clinical manifestations from 1986 to 2012 in Rio de Janeiro, Brazil

Potent antiviral activity of carbohydrate-specific algal and leguminous lectins from the Brazilian biodiversity

NICTABA and UDA, two GlcNAc-binding lectins with unique antiviral activity profiles

Binding effects of concanavalin A on a coronavirus

Lectin microarray and mass spectrometric analysis of hepatitis C proteins reveals N-linked glycosylation

Engineering of a Lectibody Targeting High-Mannose-Type Glycans of the HIV Envelope

Glycosylation of viral surface proteins probed by mass spectrometry

Lectin microarray analyses reveal host cell-specific glycan profiles of the hemagglutinins of influenza A viruses

A rapid, sensitive and selective electrochemical biosensor with concanavalin A for the preemptive detection of norovirus

Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope

The Tetrameric Plant Lectin BanLec Neutralizes HIV through Bidentate Binding to Specific Viral Glycans

Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus

Sensitivity of transmitted and founder human immunodeficiency virus type 1 envelopes to carbohydrate-binding agents griffithsin, cyanovirin-N and Galanthus nivalis agglutinin

,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile

Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases

SARS-CoV-2 and ORF3a: Nonsynonymous Mutations, Functional Domains, and Viral Pathogenesis. mSystems, 5

Targeting the Immune System with Plant Lectins to Combat Microbial Infections

Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL

Detection and Titration of Influenza A Virus Neuraminidase Inhibiting (NAI) Antibodies Using an Enzyme-Linked Lectin Assay (ELLA)

Designed oligomers of cyanovirin-N show enhanced HIV neutralization

Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle

Korean mistletoe lectin enhances natural killer cell cytotoxicity via upregulation of perforin expression

Lectin Affinity Plasmapheresis for Middle East Respiratory Syndrome-Coronavirus and Marburg Virus Glycoprotein Elimination

Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin

Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). Virusdisease

Pseudomonas aeruginosa lectin LecB impairs keratinocyte fitness by abrogating growth factor signalling

Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2

Griffithsin, a Highly Potent Broad-Spectrum Antiviral Lectin from Red Algae: From Discovery to Clinical Application

Preparation of a monoPEGylated derivative of cyanovirin-N and its virucidal effect on acyclovir-resistant strains of herpes simplex virus type 1

Feasibility of a Pilot Program for COVID-19 Convalescent Plasma Collection in Wuhan

Clinical characteristics of 225 patients with COVID-19 in a tertiary Hospital near Wuhan

Novel biosensor platforms for the detection of coronavirus infection and SARS-CoV-2

Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19

A Carbohydrate-Binding Protein from the Edible Lablab Beans Effectively Blocks the Infections of Influenza Viruses and SARS-CoV-2

Griffithsin Inhibits Nipah Virus Entry and Fusion and Can Protect Syrian Golden Hamsters From Lethal Nipah Virus Challenge

Biosensor based on lectin and lipid membranes for detection of serum glycoproteins in infected patients with dengue

Effects of recombinant Agrocybe aegerita lectin as an immunoadjuvant on immune responses

Adjuvant effects mediated by the carbohydrate recognition domain of Agrocybe aegerita lectin interacting with avian influenza H9N2 viral surface glycosylated proteins

Detection of Antibodies to HCV E1E2 by Lectin-Capture ELISA

Natural product-derived phytochemicals as potential agents against coronaviruses: a review

Anti-HIV activity of defective cyanovirin-N mutants is restored by dimerization

A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions

Crystal structure of banana lectin reveals a novel second sugar binding site

Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin

Effects of microvirin monomers and oligomers on hepatitis C virus

Antiviral lectins: Selective inhibitors of viral entry

Griffithsin tandemers: flexible and potent lectin inhibitors of the human immunodeficiency virus

Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity

Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae

Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins

Systemic effects in naive mice injected with immunomodulatory lectin ArtinM

Concanavalin A and polyvinyl butyral use as a potential dengue electrochemical biosensor

Detection of dengue virus serotypes on the surface of gold electrode based on Cratylia mollis lectin affinity

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune crossreactivity with SARS-CoV

Env glycan engagement by lectin-reengineered DAVEI protein chimera is sufficient for lytic inactivation of the virus

Lytic Inactivation of Human Immunodeficiency Virus by Dual Engagement of gp120 and gp41 Domains in the

Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)

Structure, interactions and evolutionary implications of a domain-swapped lectin dimer from Mycobacterium smegmatis

News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine

Bacterial glycans and their interactions with lectins in the innate immune system

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Comparative Analysis for Glycopatterns and Complex-Type N-Glycans of Glycoprotein in Sera from Chronic Hepatitis B-and C-Infected Patients

Alteration of liver glycopatterns during cirrhosis and tumor progression induced by HBV

Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection

Risk of the Brazilian health care system over 5572 municipalities to exceed health care capacity due to the 2019 novel coronavirus (COVID-19)

Plant Phenolics and Lectins as Vaccine Adjuvants

Are vicilins another major class of legume lectins?

Targeting and Recognition of Toll-Like Receptors by Plant and Pathogen Lectins

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

A novel anti-HIV-1 bispecific bNAb-lectin fusion protein engineered in a plant-based transient expression system

Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor

Overview of Vaccine Adjuvants: Introduction, History, and Current Status

An Engineered Microvirin Variant with Identical Structural Domains Potently Inhibits Human Immunodeficiency Virus and Hepatitis C Virus Cellular Entry

Deducing the N-and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2

Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity

Lectin-based biosensors as analytical tools for clinical oncology

Nanostructured impedimetric lectin-based biosensor for arboviruses detection

Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N

Intranasal immunization with influenza virus and Korean mistletoe lectin C (KML-C) induces heterosubtypic immunity in mice

Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination

COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives

Abnormalities of peripheral blood system in patients with COVID-19 in

Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activity

A lectin isolated from bananas is a potent inhibitor of HIV replication

Human Influenza Virus Hemagglutinins Contain Conserved Oligomannose N-Linked Glycans Allowing Potent Neutralization by Lectins

Reduction of hepatitis C virus using lectin affinity plasmapheresis in dialysis patients

Modeling hepatitis C virus therapies combining drugs and lectin affinity plasmapheresis

Investigation of the extremely weak interaction between the Japanese encephalitis virus and CLEC5A using a multivalent-interaction-enhancement sensing electrode

The Application Of Plasmapheresis For Covid-19 Patients

Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections

The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26

Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens

Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology

Envelope proteins as antiviral drug target

Understanding modern-day vaccines: what you need to know

Highly Sensitive Glycan Profiling of Hepatitis B Viral Particles and a Simple Method for Dane Particle Enrichment

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Targeting N-glycan cryptic sugar moieties for broad-spectrum virus neutralization: progress in identifying conserved molecular targets in viruses of distinct phylogenetic origins

Site-specific glycan analysis of the SARS-CoV-2 spike

Exploitation of glycosylation in enveloped virus pathobiology

Dimer of Cyanovirin-N Increases Antiviral Activity. Viruses

Preparation of monoPEGylated Cyanovirin-N's derivative and its anti-influenza A virus bioactivity in vitro and in vivo

Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan

Design of Poly(lactic-coglycolic Acid) (PLGA) Nanoparticles for Vaginal Co-Delivery of Griffithsin and Dapivirine and Their Synergistic Effect for HIV Prophylaxis

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients

COVID-19: what has been learned and to be learned about the novel coronavirus disease

PEGylation of cyanovirin-N, an entry inhibitor of HIV

A Genomic Perspective on the Origin and Emergence of SARS-CoV-2

Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: implications for vaccination and antibody therapeutics

References Griffithsin Griffithsia sp. Man Monomeric and (mGRFT) Oligomeric tandemer forms (2mGRFT, 3mGRFT, 4mGRFT) 3mGRFT and 4mGRFT exhibited improved in vitro anti-HIV action

3mGRFT showed improved action towards NiV Lo

GRFT has higher resistance to oxidation and in vivo anti-NiV action

Nostoc ellipsosporum Man Oligomers (dimers, trimers and tetramers) The dimers showed highest anti-HIV efficacy

LCVN has improved anti-HIV and anti-HSV-1 actions

PEG20k-LCVN has improved antiinfluenza H3N2 action

Chimera L5 (cyanovirin-N and 12p1) In vitro inhibition of HIV

DAVEI: Chimeric Cyanovirin-MPER formulation In vitro dual inhibition of HIV

Man Recombinant BanLec The mutation impaired the mitogenic Coves-Datson

Biosensor for detection of serum glycoproteins

Cramoll Cratylia mollis Man/Glu Biosensor for detection of serum glycoproteins

BmoLL Bauhinia monandra Gal Biosensor for detection of serum glycoproteins

GNA (or GNL) Galanthus nivalis Man Lectin affinity plasmapheresis

Gal: Galactose; Glu: glucose; Man: mannose

activity. rBanLec showed antiviral action against HIV, HCV, Influenza and Ebola.(2019); Coves-Datson, King, S.R. (2020), Swanson, Boudreaux et al. (2015) .

Oligomers (dimers, trimers and tetramers)Trimers and tetramers exhibited improved in vitro anti-HCV action. Min, Duan et al. (2017) LUMS1 with two identical structural domains.Although LUMS1 has lower cytotoxicity and immunogenicity than native microvirin, it showed lower anti-HIV and anti-HCV actions.